Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model
Akiko Nakayama(Max Planck Institute for Heart and Lung Research), Yoshikazu Ohta(University of Miyazaki), Youichi Kawakita(Takeda (Japan)), Toshiya Tamura(Takeda (Japan)), Tadashi Yusa(Takeda (Japan)), Masahiro Yaguchi(Takeda (Japan)), Akira Hayashi(Kindai University), Shinji Takagi(Takeda (Japan)), Tomoyasu Ishikawa(Takeda (Japan))
Cited by 25
Related Papers
Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein
|Journal of Biological Chemistry|2011|441
Spatial regulation of VEGF receptor endocytosis in angiogenesis
|Nature Cell Biology|2013|272
Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-<i>d</i>]pyrimidine Scaffold
|Journal of Medicinal Chemistry|2011|223
JARID1B Is a Luminal Lineage-Driving Oncogene in Breast Cancer
|Cancer Cell|2014|208
Structure-Based Approach for the Discovery of Pyrrolo[3,2-<i>d</i>]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors
|ACS Medicinal Chemistry Letters|2012|171